Physician profile
Arshjyot Narula
NPI 1831477827
$3,694.75
in general payments reported to CMS, 2019-2025
28 companies · $651 in 2025
The $651 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $230 · 2021: $334 · 2022: $469 · 2023: $302 · 2024: $516 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $735.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $424.07 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $303.80 | 2019-2022 | |
| Daiichi Sankyo INC. | $288.26 | 2019-2025 | Injectafer |
| Pfizer INC. | $248.37 | 2019-2025 | |
| Abbvie INC. | $202.48 | 2022-2024 | |
| Allergan, INC. | $161.23 | 2019 | |
| Amgen INC. | $154.64 | 2023-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $144.88 | 2019-2021 | |
| Glaxosmithkline, LLC. | $136.33 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $130.95 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Heartflow, INC. | $110.69 | 2022-2024 | Ffrct |
| Exact Sciences Corporation | $97.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $73.39 | 2019-2025 | Airsupra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $70.45 | 2024-2025 | Voquezna |
| Endogastric Solutions, INC | $62.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.55 | 2019-2021 | |
| Inari Medical, INC. | $34.88 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Scilex Pharmaceuticals INC. | $32.57 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.71 | 2019-2024 | Xifaxan, Trulance |
| Tactile Systems Technology INC | $22.32 | 2019 | |
| Circassia INC. | $18.12 | 2019 | |
| Advanced Respiratory, INC | $16.72 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.66 | 2021 | |
| Cipher Pharmaceuticals US LLC | $15.51 | 2025 | Spinosad, Natroba |
| Medtronic Minimed, INC. | $14.75 | 2019 | |
| Gilead Sciences, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshjyot Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.